TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03615950

Intervention type: DIAGNOSTIC_TEST
Intervention: Vitamin D Measurement
Description: Measurement of 25-hydroxy vitamin D levels through the blood at baseline and 12 months. If low for age, subjects will receive dietary counseling to increase intake to recommended levels. Primary care providers of enrolled subjects will be notified of abnormal results.

Intervention type: DIAGNOSTIC_TEST
Intervention: Height measurement
Description: Height will be measured at baseline and 12 months.

Intervention type: DIAGNOSTIC_TEST
Intervention: Height measurement
Description: Height will be measured at baseline and 12 months.

Intervention type: OTHER
Intervention: Assessment of medication compliance
Description: Subjects enrolled in the intervention group will undergo assessment of compliance with swallowed corticosteroids prescribed by their clinical provider. This will be performed at 6 and 12 months.
Study: NCT02822508

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BLI801 Laxative
Description: BLI801 oral laxative

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BLI801 Laxative
Description: BLI801 oral laxative

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BLI801 Laxative
Description: BLI801 oral laxative
Study: NCT03384940

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-8201a
Description: DS-8201a is comprised of an antibody component conjoined to a drug component in a lyophilized powder, which is made into solution for intravenous administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-8201a
Description: DS-8201a is comprised of an antibody component conjoined to a drug component in a lyophilized powder, which is made into solution for intravenous administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-8201a
Description: DS-8201a is comprised of an antibody component conjoined to a drug component in a lyophilized powder, which is made into solution for intravenous administration
Study: NCT03827525

Intervention type: BEHAVIORAL
Intervention: Cognitive and Behavioral Therapy
Description: 9 sessions of Cognitive and Behavioral Therapy will be realised with the patient by a clinical psychologist. They will last between 1h and 1h30.
Study: NCT00104858

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total-Body Irradiation
Description: Undergo TBI
Study: NCT04869046

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Instillation of levobupivacaine in surgical wound
Description: Once the hernia tissue had been surgically managed, the wound was sutured in layers and a solution of 0.5% levobupivacaine, 0.5 mg/kg (0.1 ml/kg), was instilled into the wound of children in the experimental group before suturing of the abdominal fascia. That same amount of 0.9% saline was given to children in the control group. The absorption of the solution took approximately 3 minutes, after which the wound was sutured. After completion of wound suturing, all children received 20 mg/kg of paracetamol administered as a rectal suppository.
Study: NCT00550407

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lamotrigine
Description: lamotrigine 100mg/day or 200mg/day
Study: NCT00557154

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ultrasound
Description: ultrasound used to identify target vein
Study: NCT04109768

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: nutrition and activity
Description: 16 sessions; nutrition 8; activity 8- 45 minutes to improve health and nutrition literacy
Study: NCT00550407

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo once daily
Study: NCT04593524

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: vitamin D 1000 IU and A 6000 IU supplementation and nutritional counseling
Description: 24 participants, which are treatment group (I) which receives nutritional counseling, vitamin D 1000 IU, vitamin A 6000 IU

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: nutritional Counseling
Description: control group (C) which only receives nutritional counseling for 28 days
Study: NCT02504489

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel + Plinabulin (DP)
Description: Docetaxel 75 mg/m2 IV + Plinabulin 30 mg/m2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel (D)
Description: Docetaxel 75 mg/m2 IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel (D)
Description: Docetaxel 75 mg/m2 IV
Study: NCT01815827

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: inclacumab
Description: single intravenous doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: inclacumab
Description: single intravenous doses
Study: NCT02418052

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: neck flexion
Description: After the cervical esophagogastric anastomoses is completed and the skin incision is closed, the patient's occiput will be lifted, and then the neck will be maintained in flexing position by an assistant. The underside of the chin will be fixed to the anterior chest wall with two stout nylon sutures by the surgeon. The neck will be fixed in the neutral flexing position for 7 to 10 days after surgery.
Study: NCT03766126

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CART123 cells; cyclophosphamide; fludarabine
Description: CART123 cells following lymphodepleting chemotherapy in patients with relapsed/refractory AML. Subjects will be treated with a split dosing approach of CART123 cells (10% Day 0; 30% Day 1; 60% Day 2) for Cohort 1a/1b or a single IV administration of CART123 cells for Cohort 2.~The total dose administered to each subject will be based on body weight obtained at the time of apheresis. Thus, the target total transduced dose, preceded by lymphodepleting chemotherapy, is 1-2x10\^6 CART123 cells/kg for Cohort 1a, 5x10\^6 CART123 cells/kg for Cohort 1b, or 2x10\^6 CART-123 cells/kg for Cohort 2. The protocol-specified minimum acceptable dose for infusion is 1x10\^5 CART123 cells/kg.
Study: NCT01006759

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise and orientation
Description: guidances for prevention of disability in leprosy with focus on hands, eyes and feet.
Study: NCT04444466

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UCB8600
Description: Study participants will receive UCB8600 in a pre-specified sequence during the Treatment Period.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Study participants will receive Placebo in a pre-specified sequence during the Treatment Period matching UCB8600.
Study: NCT02053090

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group Education and Stretching

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Group Acupuncture
Study: NCT01434849

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topical 0.5% Timolol maleate
Description: topical 0.5% Timolol aqueous solution, 1-2 drops to cover the hemangioma, twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Control (placebo) group
Description: Aqueous placebo, 1-2 drops to cover the hemangioma, twice daily
Study: NCT02203994

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Duolith® SD 1 T-Top (Storz Medical AG, Switzerland)
Description: 2000 pulses per muscle, energy level: 0.030 mJ/mm2, frequency: 4 Hz
Study: NCT00063778

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AVX101
Description: Alphavirus replicon particle vaccine expressing HIV Gag antigen

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AVX101
Description: Alphavirus replicon particle vaccine expressing HIV Gag antigen

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: phosphate buffered saline, pH 7.2, HSA, sodium gluconate, and sucrose
Study: NCT01288989

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMC-3C5
Description: Escalating doses of IMC-3C5 administered intravenously (i.v.), weekly or every other week
Study: NCT00921349

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ligation of varices
Description: all varices are ligated until obliteration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nadolol
Description: Nadolol (beta-blocker)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nadolol
Description: Nadolol (beta-blocker)
Study: NCT02160054

Intervention type: DRUG
Intervention: Graceptor®
Description: oral
Study: NCT02515734

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluorouracil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leucovorin
Study: NCT01551238

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Differences in protein content of meals
Description: Differences in protein content (energy percent) of meals
Study: NCT02515734

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Study: NCT02822508

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: BLI801 Placebo
Description: BLI801 oral laxative placebo
Study: NCT02515734

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: irinotecan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oxaliplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Study: NCT04135638

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Cover Group
Description: Cover when the ILM flap is everted over the MH gap in a single layer

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Fill Group
Description: Fill when the ILM is folded into multiple layers within the MH
Study: NCT00347152

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Divalproex
Description: Divalproex, 8-20% taper

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Divalproex
Description: Divalproex, 8-20% taper
Study: NCT02515734

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: bevacizumab

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cetuximab
Study: NCT03449719

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT - Ablative radiation Therapy
Description: The current phase II randomized trial,Ablative Radiation Therapy in patients with Oligometastatic castration resistant prostate cancer (ARTO trial) aims to evaluate the difference in PSA response rate between the experimental arm (AA+SBRT) and control arm (AA) in metastatic castration-resistant prostate cancer patients.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abiraterone Acetate
Description: systemic treatment with abiraterone acetate 1000 mg daily and prednisone 10 mg daily, plus GnRH agonist or antagonist

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone Acetate
Description: systemic treatment with abiraterone acetate 1000 mg daily and prednisone 10 mg daily, plus GnRH agonist or antagonist
Study: NCT03642509

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Left atrial appendage occlusion
Description: Interventional left atrial appendage occlusion with the Amulet or Watchman device

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NOAC
Description: Medical treatment arm. Patients will be treated with one of the available NOAC drugs; Apixaban, Dabigatran, Edoxaban or Rivaroxaban. The specific drug and dose is at the discretion of the treating physician.
Study: NCT03201419

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FE 201836
Description: Oral solution for daily intake

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FE 201836
Description: Oral solution for daily intake

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FE 201836
Description: Oral solution for daily intake

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FE 201836
Description: Oral solution for daily intake

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FE 201836
Description: Oral solution for daily intake

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FE 201836
Description: Oral solution for daily intake

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desmopressin
Description: Desmopressin Orally Disintegrating Tablet (ODT)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desmopressin
Description: Desmopressin Orally Disintegrating Tablet (ODT)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo oral solution
Description: Manufactured to mimic experimental drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo oral solution
Description: Manufactured to mimic experimental drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo oral solution
Description: Manufactured to mimic experimental drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo ODT
Description: Manufactured to mimic experimental drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo ODT
Description: Manufactured to mimic experimental drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo ODT
Description: Manufactured to mimic experimental drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo ODT
Description: Manufactured to mimic experimental drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo ODT
Description: Manufactured to mimic experimental drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo ODT
Description: Manufactured to mimic experimental drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo ODT
Description: Manufactured to mimic experimental drug
Study: NCT04181346

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin
Description: antipsychotic

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study: NCT01259180

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: acupuncture treatment
Description: twice a week, 6 weeks, 12sessions penetrating skin with stailess steel acupuncture device(diameter: 0.25-0.3mm,legth: 30-70mm) points: BL 23,BL31,BL32, BL40, BL53, GB30, SP 6 bilaterally plus Ashi. with

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham acupunture
Description: twice a week, 6 weeks, 12 sessions not penetrating skin with dull acupuncture device(Park Sham device :Acuprime Co. Ltd, UK) point: 1\~2inches away from real acupuncture point
Study: NCT03025984

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Texting
Description: patient adherence to her recommended care regimen after intervention of a text message reminder and education system
Study: NCT02825615

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radial artery cannulation
Description: Radial artery cannulation done with conventional and ultrasound guidance in two respective groups of patients and their first pass success and ultimate success rates compared in different hemodynamic subsets of the patients.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radial artery cannulation
Description: Radial artery cannulation done with conventional and ultrasound guidance in two respective groups of patients and their first pass success and ultimate success rates compared in different hemodynamic subsets of the patients.
Study: NCT01458483

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Baroreceptor Stimulation
Description: The stimulation catheter may be placed in different locations within the IJV at the level of the cervical spine vertebrae. Stimulation amplitudes will be varied from 0.1 mA to 20 mA.
Study: NCT01200303

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: non-cathartic CTC
Description: non-cathartic, CAD-assisted CT Colonography
Study: NCT01817504

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Systematic transplantectomy
Description: Transplantectomy within two months after return to dialyse. Antiproliferatives stop at the start of dialysis. Maintenance basic immunosuppressive treatment without dose reduction up to two weeks after transplantectomy. Abrupt discontinuation of the basic immunosuppressive treatment ttwo weeks after transplantectomy. Maintenance corticosteroids at 5mg per day until one month after transplantectomy then stop corticosteroids within one month.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Progressive reduction of immunosuppression
Description: Progressive reduction of immunosuppression. Transplantectomy for cause only. Antiproliferatives withdrawn at the start of dialysis. Maintenance of anticalcineurin or mTOR inhibitors half dose for 3 months, ¼ dose for 3 months and then stop. Maintenance corticosteroids for 6 months up to 5 mg per day, and then soft stop in 3 months.~In case of transplantectomy by reason in the control group, basic immunosuppression will be continued at the maintenance dose during the current surgical procedure, and withdrawn two weeks later, similary to the strategy used in the study group.
Study: NCT04266132

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: General anaesthesia
Description: General anaesthesia will be induced with 8% sevoflurane in oxygen and maintained with 1 MAC sevoflurane via a laryngeal mask.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: General anaesthesia
Description: General anaesthesia will be induced with 8% sevoflurane in oxygen and maintained with 1 MAC sevoflurane via a laryngeal mask.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound-guided RLB
Description: The suggested ultrasound transducer orientation is sagittal paramedian (cephalacaudad direction). We begin our ultrasound scanning in a paramedian sagittal plane by finding desired level (T12- L1).The transverse process view, the costotransverse ligament can be visualized above the paravertebral space. Continuing to scan from lateral to medial, the vertebral laminae come into view.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound-guided INB
Description: A high-frequency probe is placed medial to the anterior superior iliac spine with the axis facing the umbilicus. A needle is inserted toward the ilioinguinal nerve as it runs between the transversus abdominis and internal oblique.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: 0.3 ml.kg of 0.25% bupivacaine will be injected under visualization.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: 0.3 ml.kg of 0.25% bupivacaine will be injected under visualization.
Study: NCT00001595

Intervention type: PROCEDURE
Intervention: MRI

Intervention type: PROCEDURE
Intervention: Tissue specimen collection
Study: NCT02851706

Intervention type: OTHER
Intervention: No Treatment
Description: Survey or Questionnaire Completion with or without Sample Submission

Intervention type: OTHER
Intervention: No Treatment
Description: Survey or Questionnaire Completion with or without Sample Submission
Study: NCT03267004

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dietary Assessment of Meal A using images taken by Sony Smarteyeglass
Description: Participant will be wearing Sony Smarteyeglass to record digital images while eating meal A in the laboratory~Meal A:~Turkey and Provolone Cheese Sandwich \[whole wheat bread 52g(female \& male), Turkey 70g(female) \& 133g(male), Provolone cheese 23g(female \& male), tomato 50g(female \& male), lettuce 45g(female \& male)\]; Chicken and wild rice \[chicken 98g(female \& male), wild rice 71g(female) \& 107g(male)\]; chocolate chips cookies \[44g(female) \& 60.5g(male)\]; potato chips \[39g(female) \& 52g(male)\].

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dietary Assessment of Meal A using images taken by Sony Smarteyeglass
Description: Participant will be wearing Sony Smarteyeglass to record digital images while eating meal A in the laboratory~Meal A:~Turkey and Provolone Cheese Sandwich \[whole wheat bread 52g(female \& male), Turkey 70g(female) \& 133g(male), Provolone cheese 23g(female \& male), tomato 50g(female \& male), lettuce 45g(female \& male)\]; Chicken and wild rice \[chicken 98g(female \& male), wild rice 71g(female) \& 107g(male)\]; chocolate chips cookies \[44g(female) \& 60.5g(male)\]; potato chips \[39g(female) \& 52g(male)\].

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dietary Assessment of Meal B using Images taken by Sony Smarteyeglass
Description: Participant will be wearing Sony Smarteyeglass to record digital images while eating meal B in the laboratory~Meal B:~Ham \& Cheddar cheese wrap \[Tortilla 45g(female \& male), Ham deli 76g(female) \& 103g(male), cheddar cheese 21g(female) \& 32g(male), Spring Mix 36g(female \& male), Fat Free ranch dressing 29g(female \& male)\]; Pasta with broccoli and Alfredo sauce \[Pasta 91g(female) \& 121g(male), Broccoli 66g(female \& male), Alfredo sauce 38g(female) \& 50g(male)\]; Chocolate Ice-cream \[107g(female), 138g(male)\]; Red seedless grapes \[365g (female), 471g(male)\].

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dietary Assessment of Meal B using Images taken by Sony Smarteyeglass
Description: Participant will be wearing Sony Smarteyeglass to record digital images while eating meal B in the laboratory~Meal B:~Ham \& Cheddar cheese wrap \[Tortilla 45g(female \& male), Ham deli 76g(female) \& 103g(male), cheddar cheese 21g(female) \& 32g(male), Spring Mix 36g(female \& male), Fat Free ranch dressing 29g(female \& male)\]; Pasta with broccoli and Alfredo sauce \[Pasta 91g(female) \& 121g(male), Broccoli 66g(female \& male), Alfredo sauce 38g(female) \& 50g(male)\]; Chocolate Ice-cream \[107g(female), 138g(male)\]; Red seedless grapes \[365g (female), 471g(male)\].
Study: NCT00069069

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intransal instillation of E-selectin
Description: Intranasal recombinant human E-selectin
Study: NCT02000466

Intervention type: OTHER
Intervention: Data collection
Description: Initial and follow-up data will be collected using questionnaires
Study: NCT04951895

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI
Description: MRI of TMJ

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI
Description: MRI of TMJ
Study: NCT01440075

Intervention type: OTHER
Group type: OTHER
Intervention: Cardiac evaluation
Description: complete cardiac evaluation with :~Electrocardiogram Echodoppler Echodoppler with dobutamine stress Carotid Echodoppler Coronary scan Positron emission tomography with adenosine stress Blood test (search for early atherosclerosis marker Genotyping

Intervention type: OTHER
Group type: OTHER
Intervention: Cardiac evaluation
Description: complete cardiac evaluation with :~Electrocardiogram Echodoppler Echodoppler with dobutamine stress Carotid Echodoppler Coronary scan Positron emission tomography with adenosine stress Blood test (search for early atherosclerosis marker Genotyping
Study: NCT04210882

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Moderate-Intensity Exercise
Description: See description of study arm.